Why not [symbol: see text]zanamivir?
In 1999, Drug and Therapeutics Bulletin (DTB) and the National Institute for Clinical Excellence (NICE) concluded independently that [symbol: see text]zanamivir (Relenza) should not be used in managing patients with influenza. Recently, reviewing further evidence, NICE revised its position regarding use of zanamivir in 'at-risk' adults: it recommends that, under specific circumstances, the drug should be prescribed for patients at risk who are able start treatment within 48 hours of the onset of influenza-like symptoms. We disagree with this revised advice reasons we explain here.
D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D006146:Guanidines; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy*; D008875:Middle Aged; D018579:Patient Selection; D011714:Pyrans; D012794:Sialic Acids / Q000627:therapeutic use*; D016896:Treatment Outcome; D053243:Zanamivir
D000998:Antiviral Agents; D006146:Guanidines; D011714:Pyrans; D012794:Sialic Acids; D053243:Zanamivir